Get the Stockscreener App
219.48
0.66%
1.36
Biogen Inc stock is traded at $219.48, with a volume of 31,131.
It is up +0.66% in the last 24 hours and up +8.59% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$218.12
Open:
$218.93
24h Volume:
31,131
Relative Volume:
0.03
Market Cap:
$32.43B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
23.55
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+3.30%
1M Performance:
+8.59%
6M Performance:
+15.11%
1Y Performance:
+61.01%
1-Day Range:
$218.00
$220.22
1-Week Range:
$213.96
$222.15
52-Week Range:
$131.52
$222.15
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
219.49 | 31.67B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,253.90 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.81 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.39 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
153.06 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.62 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial - TipRanks
Biogen Inc. (NASDAQ:BIIB) Healthcare Momentum Draws Fresh Market Attention - Kalkine Media
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders - Yahoo Finance
OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 16,529 Biogen Inc. $BIIB - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 13,000 Biogen Inc. $BIIB - MarketBeat
66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen (BIIB) And The Alzheimer’s Narrative As Valuation Stays In Focus - simplywall.st
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? - TradingView
Impax Global Women's Leadership Fund's Biogen Inc(BIIB) Holding History - GuruFocus
Is Wall Street Bullish or Bearish on Biogen Stock? - Barchart.com
Meeder Advisory Services Inc. Acquires Shares of 4,608 Biogen Inc. $BIIB - MarketBeat
Edmond DE Rothschild Holding S.A. Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc (BIIB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.
Biogen Inc (BIIB) Stock Up 4.2% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen (NASDAQ:BIIB) Sets New 1-Year HighTime to Buy? - MarketBeat
Biogen (BIIB) Stock Surges to 52-Week Peak After BlackRock’s $3.4B Investment - Blockonomi
Biogen stock hits 52-week high at 219.94 USD - Investing.com
Biogen stock holds above $212 as Leqembi momentum grows - ad-hoc-news.de
Mitsubishi UFJ Asset Management Co. Ltd. Takes $77.53 Million Position in Biogen Inc. $BIIB - MarketBeat
Deutsche Bank AG Takes $193.16 Million Position in Biogen Inc. $BIIB - MarketBeat
15,985,736 Shares in Biogen Inc. $BIIB Bought by BlackRock Inc. - MarketBeat
Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Biogen stock holds near $209 after Q2 beat - AD HOC NEWS
Pallas Capital Advisors LLC Acquires Shares of 12,859 Biogen Inc. $BIIB - MarketBeat
K.J. Harrison & Partners Inc Makes New $2.16 Million Investment in Biogen Inc. $BIIB - MarketBeat
Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB - MarketBeat
Lantheus Wins FDA Approval for Alzheimer's Tau PET Imaging Agent - finance.biggo.com
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating - ChartMill
Biogen stock holds steady as new Alzheimer’s imaging agent reshapes dementia diagnostics - Ad-hoc-news.de
Nippon Life Global Investors Americas Inc. Buys New Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (BIIB) Investor Outlook: Exploring A Promising 13.23% Potential Upside - DirectorsTalk Interviews
Focus Partners Advisor Solutions LLC Buys New Position in Biogen Inc. $BIIB - MarketBeat
NewEdge Advisors LLC Trims Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc.: Target Price Consensus and Analysts Recommendations | 0R1B | US09062X1037 - marketscreener.com
Biogen Stock (BIIB) Opinions on Analyst Upgrade and Acquisition - Quiver Quantitative
Biogen (BIIB) Edges Higher to $210.65 as Biotech Sentiment FirmsQuality ETF - vinanet.vn
Wolfe Research Issues Rare Double Upgrade for Biogen and AbbVie, Setting $300 Targets - finance.biggo.com
BIIB Upgraded by Wolfe Research -- Price Target Raised to $300 - GuruFocus
Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation - Yahoo Finance
Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300 - marketscreener.com
Handelsbanken Fonder AB Has $20.14 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
BIIB Q2 2026 Earnings: Strong EPS Surprise of 19.75% Lifts SharesAnnual Report - vinanet.vn
Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’ - Pharma Voice
Insight Wealth Strategies LLC Has $7.20 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):